Table 3.

Breast cancer risks of the 15 genes stratified by ER, PR, and HER2 status of breast cancer cases

Gene	ER and/or PR+, and HER2-cases (n = 4,421)		HER2+ cases (n = 1,847)		ER-, PR-, and HER2-cases (n = 1,103)		ER/PR/HER2 unknown cases (n = 696)
	No. of carriers (%)	OR (95% CI)	No. of carriers (%)	OR (95% CI)	No. of carriers (%)	OR (95% CI)	No. of carriers (%)	OR (95% CI)
TP53	16 (0.36)	15.9 (4.6–54.6)	10 (0.54)	23.8 (6.5–86.6)	2 (0.18)	7.9 (1.3–47.6)	3 (0.43)	18.9 (3.8–94.0)
BRCA2	190 (4.30)	12.8 (8.9–17.7)	29 (1.57)	4.5 (2.8–7.2)	44 (3.99)	11.8 (7.8–17.9)	21 (3.02)	8.8 (5.3–14.9)
BRCA1	47 (1.06)	5.6 (3.5–9.2)	12 (0.65)	3.4 (1.7–6.8)	82 (7.43)	42.1 (26.8–66.2)	5 (0.72)	3.8 (1.4–9.9)
PALB2	36 (0.81)	6.0 (3.4–10.5)	8 (0.43)	3.2 (1.4–7.3)	13 (1.18)	8.7 (4.2–17.8)	0 (0.00)	–
BARD1	4 (0.09)	1.5 (0.4–4.9)	2 (0.11)	1.8 (0.4–8.4)	8 (0.73)	12.0 (4.5–32.0)	1 (0.14)	2.3 (0.3–18.9)
CHEK2	14 (0.32)	2.5 (1.2–5.0)	9 (0.49)	3.8 (1.7–8.5)	1 (0.09)	0.7 (0.1–5.3)	2 (0.29)	2.2 (0.5–9.6)
RAD51D	11 (0.25)	1.4 (0.7–2.9)	6 (0.32)	1.9 (0.8–4.6)	12 (1.09)	6.3 (3.1–12.6)	2 (0.29)	1.6 (0.4–7.0)
ATM	22 (0.50)	2.7 (1.5–4.9)	5 (0.27)	1.5 (0.6–3.9)	1 (0.09)	0.5 (0.1–3.7)	3 (0.43)	2.4 (0.7–7.9)
PTEN	4 (0.09)	–	1 (0.05)	–	0 (0.00)	–	0 (0.00)	–
CDH1	0 (0.00)	–	0 (0.00)	–	1 (0.09)	–	0 (0.00)	–
STK11	1 (0.02)	3.0 (0.2–47.5)	0 (0.00)	–	0 (0.00)	–	0 (0.00)	–
NBN	5 (0.11)	3.0 (0.9–10.3)	1 (0.05)	1.4 (0.2–12.2)	0 (0.00)	–	0 (0.00)	–
RAD50	14 (0.32)	1.3 (0.7–2.5)	3 (0.16)	0.7 (0.2–2.3)	3 (0.27)	1.2 (0.4–3.8)	1 (0.14)	0.6 (0.08–4.5)
BRIP1	6 (0.14)	0.6 (0.3–1.5)	3 (0.16)	0.7 (0.2–2.4)	2 (0.18)	0.8 (0.2–3.4)	0 (0.00)	–
RAD51C	0 (0.00)	–	2 (0.11)	0.6 (0.2–2.7)	0 (0.00)	–	0 (0.00)	–

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; OR, odds ratio; CI, confidence interval.